Drugs / Clostridium butyricum CBM588 Strain
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07037004 | Jan 2027 → Oct 2028 expected | clear cell renal carcinoma, sarcomatoid renal cell carcinoma | City of Hope Medical Center | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Clostridium butyricum CBM588 Strain | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07037004 ↗ |
| Modality | Other / unclassified | “CBM588, a Live Biotherapeutic Product (LBP) containing a bacteria called Clostridium butyricum” NCT07037004 ↗ |
| Route | Oral | “Given PO” NCT07037004 ↗ |